Matches in SemOpenAlex for { <https://semopenalex.org/work/W2403820072> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2403820072 endingPage "9" @default.
- W2403820072 startingPage "4023" @default.
- W2403820072 abstract "Prognosis of advanced ovarian cancer is unsatisfactory. Chemotherapy can be intensified combining active drugs at their highest possible doses.In this phase I/II trial, 77 untreated patients received escalating doses of paclitaxel (135, 155, 175, 195 and 215 mg/m2, infused over 3 hours) with carboplatin (AUC 3.6) and cisplatin (60 mg/m2). Nine, 16, 13, 8 and 3 patients were treated at the five levels, respectively. A further 28 patients were treated at the maximum tolerable dose (MTD).Dose-limiting toxicities (one WHO grade 3 constipation, one grade 2 prolonged peripheral neurotoxicity and one grade 3 cardiac toxicity) occurred at 215 mg/m2 in 3 out of 3 patients. MTD was reached at level 4 paclitaxel dose (195 mg/m2). Response was evaluated in 62 patients. A complete response was achieved in 23 patients (37.1%-95% CI 25.2-50.3), including 16 (25.8%) pathological and partial response in 28 (45.2%), for an overall response rate of 82.3% (95% exact CL: 70.5%-90.8%). The probability of response was affected by the degree of initial debulking (p = 0.002) and not by the paclitaxel dose. In patients with stage III-IV disease, median progression-free survival was 17 months (95% CI 14-25). After a median follow-up of 28 months, median survival had not been reached; 2-year estimated survival was 67%.Paclitaxel can be safely given at the dose of 195 mg/m2 in combination with carboplatin (AUC 3.6) and cisplatin (60 mg/m2). This combination is active and safe and could be considered in clinical settings requiring intensive short treatment." @default.
- W2403820072 created "2016-06-24" @default.
- W2403820072 creator A5015740152 @default.
- W2403820072 creator A5016655393 @default.
- W2403820072 creator A5046099565 @default.
- W2403820072 creator A5054539855 @default.
- W2403820072 creator A5076585315 @default.
- W2403820072 creator A5078562748 @default.
- W2403820072 creator A5079216222 @default.
- W2403820072 creator A5082076973 @default.
- W2403820072 creator A5082306007 @default.
- W2403820072 creator A5083659627 @default.
- W2403820072 creator A5084227120 @default.
- W2403820072 creator A5086820898 @default.
- W2403820072 date "2001-03-28" @default.
- W2403820072 modified "2023-09-23" @default.
- W2403820072 title "Carboplatin, cisplatin and paclitaxel in the treatment of patients with epithelial ovarian cancer." @default.
- W2403820072 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11268496" @default.
- W2403820072 hasPublicationYear "2001" @default.
- W2403820072 type Work @default.
- W2403820072 sameAs 2403820072 @default.
- W2403820072 citedByCount "1" @default.
- W2403820072 crossrefType "journal-article" @default.
- W2403820072 hasAuthorship W2403820072A5015740152 @default.
- W2403820072 hasAuthorship W2403820072A5016655393 @default.
- W2403820072 hasAuthorship W2403820072A5046099565 @default.
- W2403820072 hasAuthorship W2403820072A5054539855 @default.
- W2403820072 hasAuthorship W2403820072A5076585315 @default.
- W2403820072 hasAuthorship W2403820072A5078562748 @default.
- W2403820072 hasAuthorship W2403820072A5079216222 @default.
- W2403820072 hasAuthorship W2403820072A5082076973 @default.
- W2403820072 hasAuthorship W2403820072A5082306007 @default.
- W2403820072 hasAuthorship W2403820072A5083659627 @default.
- W2403820072 hasAuthorship W2403820072A5084227120 @default.
- W2403820072 hasAuthorship W2403820072A5086820898 @default.
- W2403820072 hasConcept C121608353 @default.
- W2403820072 hasConcept C126322002 @default.
- W2403820072 hasConcept C126894567 @default.
- W2403820072 hasConcept C141071460 @default.
- W2403820072 hasConcept C143998085 @default.
- W2403820072 hasConcept C2776694085 @default.
- W2403820072 hasConcept C2777292972 @default.
- W2403820072 hasConcept C2778239845 @default.
- W2403820072 hasConcept C2780427987 @default.
- W2403820072 hasConcept C2781100745 @default.
- W2403820072 hasConcept C2781451048 @default.
- W2403820072 hasConcept C29730261 @default.
- W2403820072 hasConcept C71924100 @default.
- W2403820072 hasConcept C90924648 @default.
- W2403820072 hasConceptScore W2403820072C121608353 @default.
- W2403820072 hasConceptScore W2403820072C126322002 @default.
- W2403820072 hasConceptScore W2403820072C126894567 @default.
- W2403820072 hasConceptScore W2403820072C141071460 @default.
- W2403820072 hasConceptScore W2403820072C143998085 @default.
- W2403820072 hasConceptScore W2403820072C2776694085 @default.
- W2403820072 hasConceptScore W2403820072C2777292972 @default.
- W2403820072 hasConceptScore W2403820072C2778239845 @default.
- W2403820072 hasConceptScore W2403820072C2780427987 @default.
- W2403820072 hasConceptScore W2403820072C2781100745 @default.
- W2403820072 hasConceptScore W2403820072C2781451048 @default.
- W2403820072 hasConceptScore W2403820072C29730261 @default.
- W2403820072 hasConceptScore W2403820072C71924100 @default.
- W2403820072 hasConceptScore W2403820072C90924648 @default.
- W2403820072 hasIssue "5C" @default.
- W2403820072 hasLocation W24038200721 @default.
- W2403820072 hasOpenAccess W2403820072 @default.
- W2403820072 hasPrimaryLocation W24038200721 @default.
- W2403820072 hasRelatedWork W2060767396 @default.
- W2403820072 hasRelatedWork W2075452221 @default.
- W2403820072 hasRelatedWork W2105623825 @default.
- W2403820072 hasRelatedWork W2321468987 @default.
- W2403820072 hasRelatedWork W2400212447 @default.
- W2403820072 hasRelatedWork W2410995755 @default.
- W2403820072 hasRelatedWork W2411320658 @default.
- W2403820072 hasRelatedWork W2415703278 @default.
- W2403820072 hasRelatedWork W2417634857 @default.
- W2403820072 hasRelatedWork W2530877275 @default.
- W2403820072 hasVolume "20" @default.
- W2403820072 isParatext "false" @default.
- W2403820072 isRetracted "false" @default.
- W2403820072 magId "2403820072" @default.
- W2403820072 workType "article" @default.